Telesis Bio Announces First Commercial Shipment Of BioXp Select DNA Cloning Kit
Portfolio Pulse from Benzinga Newsdesk
Telesis Bio Inc. (NASDAQ:TBIO) announced the first commercial shipment of its BioXp Select DNA Cloning kit, which enables on-demand and automated assembly of DNA fragments. The kit is expected to help researchers optimize and accelerate their discovery workflows by providing greater workflow flexibility and automation.
May 22, 2023 | 4:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Telesis Bio's first commercial shipment of the BioXp Select DNA Cloning kit is expected to help researchers optimize and accelerate their discovery workflows, potentially increasing demand for the product.
The BioXp Select DNA Cloning kit allows researchers to automate the assembly of DNA fragments, which can help them overcome bottlenecks created by long synthesis lead times and streamline their workflows. This increased efficiency and automation could lead to higher demand for the product, positively impacting Telesis Bio's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100